A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
Brown
Dearg S
DS
AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. dearg.brown@astrazeneca.com
Belfield
Andrew J
AJ
Brown
George R
GR
Campbell
Douglas
D
Foubister
Alan
A
Masters
David J
DJ
Pike
Kurt G
KG
Snelson
Wendy L
WL
Wells
Stuart L
SL
D000577:Amides / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D018501:Antirheumatic Agents / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D066298:In Vitro Techniques; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D051381:Rats; D013329:Structure-Activity Relationship; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
D000577:Amides; D018501:Antirheumatic Agents; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D048051:p38 Mitogen-Activated Protein Kinases